Literature DB >> 20620888

Physical health in schizophrenia: a challenge for antipsychotic therapy.

A Heald1.   

Abstract

In the management of schizophrenia, mental health outcomes are the principal focus of treatment. The objective is to control the psychotic symptoms while minimising negative features of the illness, to achieve an overall improvement in the societal functioning of patients. Physical health is also important because if it is compromised, many of the benefits of improved mental health will be offset. Compared with the general population, schizophrenia patients are at increased risk of weight gain, abdominal obesity, diabetes, metabolic syndrome, and cardiovascular disease. These physical health problems can contribute to the decreased quality of life, lowered self-esteem and reduced life expectancy commonly reported in schizophrenia. For these reasons there is a pressing need to improve both the monitoring and the management of physical health in patients with schizophrenia as a part of their overall care. A consensus for metabolic monitoring of patients receiving treatment with antipsychotic drugs is available. However, the practicing clinician requires guidance about management of physical health in routine clinical practice. This should include recommendations for measurements that have strong predictive value about physical health risks yet are easy to make, and about the use of medications that have the least effect on physical health parameters. This article will review the gravity of the physical health risks facing schizophrenia patients. Copyright (c) 2010 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20620888     DOI: 10.1016/S0924-9338(10)71700-4

Source DB:  PubMed          Journal:  Eur Psychiatry        ISSN: 0924-9338            Impact factor:   5.361


  10 in total

1.  Trends in standardized mortality among individuals with schizophrenia, 1993-2012: a population-based, repeated cross-sectional study.

Authors:  Evgenia Gatov; Laura Rosella; Maria Chiu; Paul A Kurdyak
Journal:  CMAJ       Date:  2017-09-18       Impact factor: 8.262

2.  Diabetes is associated with lower global cognitive function in schizophrenia.

Authors:  Yoichiro Takayanagi; Nicola G Cascella; Akira Sawa; William W Eaton
Journal:  Schizophr Res       Date:  2012-09-29       Impact factor: 4.939

Review 3.  Health promotion lifestyle interventions for weight management in psychosis: a systematic review and meta-analysis of randomised controlled trials.

Authors:  Elena Bonfioli; Loretta Berti; Claudia Goss; Francesca Muraro; Lorenzo Burti
Journal:  BMC Psychiatry       Date:  2012-07-12       Impact factor: 3.630

Review 4.  Effective lifestyle interventions to improve type II diabetes self-management for those with schizophrenia or schizoaffective disorder: a systematic review.

Authors:  Adriana Cimo; Erene Stergiopoulos; Chiachen Cheng; Sarah Bonato; Carolyn S Dewa
Journal:  BMC Psychiatry       Date:  2012-03-23       Impact factor: 3.630

5.  Chronic pain diagnoses and opioid dispensings among insured individuals with serious mental illness.

Authors:  Ashli Owen-Smith; Christine Stewart; Musu M Sesay; Sheryl M Strasser; Bobbi Jo Yarborough; Brian Ahmedani; Lisa R Miller-Matero; Stephen C Waring; Irina V Haller; Beth E Waitzfelder; Stacy A Sterling; Cynthia I Campbell; Rulin C Hechter; John E Zeber; Laurel A Copeland; Jeffrey F Scherrer; Rebecca Rossom; Greg Simon
Journal:  BMC Psychiatry       Date:  2020-01-31       Impact factor: 3.630

6.  Weight gain and comorbidities associated with oral second-generation antipsychotics: analysis of real-world data for patients with schizophrenia or bipolar I disorder.

Authors:  Michael J Doane; Leona Bessonova; Haley S Friedler; Kathleen M Mortimer; Harry Cheng; Thomas Brecht; Amy K O'Sullivan; Hannah Cummings; David McDonnell; Jonathan M Meyer
Journal:  BMC Psychiatry       Date:  2022-02-14       Impact factor: 3.630

7.  Examining Side Effect Variability of Antipsychotic Treatment in Schizophrenia Spectrum Disorders: A Meta-analysis of Variance.

Authors:  Maria S Neumeier; Stephanie Homan; Stefan Vetter; Erich Seifritz; John M Kane; Maximilian Huhn; Stefan Leucht; Philipp Homan
Journal:  Schizophr Bull       Date:  2021-10-21       Impact factor: 7.348

8.  Detection of subclinical atherosclerosis and diastolic dysfunction in patients with schizophrenia.

Authors:  Cüneyt Unsal; Mustafa Oran; Hande Oktay Tureli; Seref Alpsoy; Sema Yeşilyurt; Mehtap Arslan; Birol Topcu; Osman Karakaya; Erhan Kurt
Journal:  Neuropsychiatr Dis Treat       Date:  2013-10-08       Impact factor: 2.570

9.  Evaluation of the physical health of adolescent in-patients in generic and secure services: retrospective case-note review.

Authors:  Rebekah Carney; Shermin Imran; Heather Law; Siri Folstad; Sophie Parker
Journal:  BJPsych Bull       Date:  2020-06

10.  Neurological soft signs and cognition in the late course of chronic schizophrenia: a longitudinal study.

Authors:  Christina J Herold; Céline Z Duval; Johannes Schröder
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2020-05-16       Impact factor: 5.270

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.